Search

Fagron

Uždarymo kaina

SektoriusSveikatos priežiūra

21.8 -0.91

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

21.7

Max

21.95

Pagrindiniai rodikliai

By Trading Economics

Pajamos

46M

Pardavimai

476M

P/E

Sektoriaus vid.

18.547

87.826

Dividendų pajamingumas

1.61

Pelno marža

9.569

Darbuotojai

3,989

EBITDA

87M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+20.59% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

1.61%

2.26%

Kitas uždarbis

2026-02-19

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.6B

Ankstesnė atidarymo kaina

22.71

Ankstesnė uždarymo kaina

21.8

Naujienos nuotaikos

By Acuity

15%

85%

19 / 372 reitingas Healthcare

Fagron Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-07 23:11; UTC

Uždarbis

Samsung Electronics Expects Record Fourth-Quarter Profit Beat

2026-01-07 22:55; UTC

Pagrindinės rinkos jėgos

Defense Stocks Rebound After Trump Says He Wants $1.5 Trillion Military Budget in 2027

2026-01-07 21:39; UTC

Pagrindinės rinkos jėgos

Raytheon Down Following Trump Post Criticizing Company

2026-01-07 20:13; UTC

Pagrindinės rinkos jėgos

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

2026-01-07 20:03; UTC

Pagrindinės rinkos jėgos

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Executive Pay

2026-01-07 23:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-07 23:46; UTC

Rinkos pokalbiai

Nikkei May Decline as China-Japan Tensions Linger -- Market Talk

2026-01-07 23:42; UTC

Įsigijimai, susijungimai, perėmimai

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 5th Update

2026-01-07 23:34; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Lingering Geopolitical Risks -- Market Talk

2026-01-07 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Constellation Closes Deal for Calpine, Creating Biggest Electricity Generator -- Barrons.com

2026-01-07 22:48; UTC

Rinkos pokalbiai

Infratil's Discount to Net Asset Value Too Good to Ignore -- Market Talk

2026-01-07 22:46; UTC

Uždarbis

Samsung Electronics Estimates 2025 Rev KRW332.770T Vs KRW300.870T >005930.SE

2026-01-07 22:45; UTC

Uždarbis

Samsung Electronics Estimates 2025 Oper Pft KRW43.530T Vs KRW32.730T >005930.SE

2026-01-07 22:43; UTC

Įsigijimai, susijungimai, perėmimai

Revolution Medicines Draws Takeover Interest -- 2nd Update

2026-01-07 22:42; UTC

Uždarbis

Samsung Electronics 4Q Oper Pft Estimate Beat FactSet-Compiled Consensus Forecast

2026-01-07 22:41; UTC

Uždarbis

Samsung Electronics Sees 4Q Oper Pft KRW20.000T Vs KRW6.490T >005930.SE

2026-01-07 22:41; UTC

Uždarbis

Samsung Electronics Sees 4Q Rev KRW93.000T Vs KRW75.790T >005930.SE

2026-01-07 22:40; UTC

Pagrindinės rinkos jėgos

Defense Stocks Rebound After Trump Says He Wants $1.5T Military Budget in 2027

2026-01-07 22:31; UTC

Rinkos pokalbiai

Macro Tailwinds Strengthen for Chalice Mining -- Market Talk

2026-01-07 22:22; UTC

Rinkos pokalbiai

Northern Star's Run of Disruptions Increasingly a Concern -- Market Talk

2026-01-07 22:01; UTC

Rinkos pokalbiai

Valuations of New Zealand Property Stocks Supportive -- Market Talk

2026-01-07 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-07 21:46; UTC

Rinkos pokalbiai

Northern Star's Revised Guidance Looks Achievable -- Market Talk

2026-01-07 21:22; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly to Buy Ventyx Biosciences for $14 a Share >LLY VTYX

2026-01-07 21:18; UTC

Įsigijimai, susijungimai, perėmimai

Lilly To Acquire Ventyx Biosciences To Advance Oral Therapies Targeting Inflammatory-mediated Diseases >LLY VTYX

2026-01-07 21:05; UTC

Įsigijimai, susijungimai, perėmimai

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 4th Update

2026-01-07 20:29; UTC

Įsigijimai, susijungimai, perėmimai

AbbVie Near Deal for Revolution Medicines -- Update

2026-01-07 20:27; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

2026-01-07 19:58; UTC

Rinkos pokalbiai

Oil Falls As U.S. to Receive Sanctioned Venezuelan Crude -- Market Talk

2026-01-07 19:48; UTC

Pagrindinės rinkos jėgos

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Exec Pay

Fagron Prognozė

Kainos tikslas

By TipRanks

20.59% į viršų

12 mėnesių prognozė

Vidutinis 19.5 EUR  20.59%

Aukščiausias 19.5 EUR

Žemiausias 19.5 EUR

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Fagron kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

19 / 372 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Fagron

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
help-icon Live chat